ASML Raises 2026 Outlook as AI Chip Demand Lifts Q2 Earnings 
BHP Faces Major Port Hedland Strike as Labor Talks Stall Ahead of Production Report 
DeepSeek Eyes China IPO as AI Startup Seeks $71 Billion Valuation in New Funding Round 
UBS Boosts China Tech Bets, Adds Kuaishou and Meituan to Focus List 
Airbus Signs Cloud Deal With Scaleway to Power Secure AI and Defense Applications 
Taiwan Mangoes Head to Europe as Premium Fruit Exports Expand 
Richemont Q1 Sales Beat Forecast as Cartier Demand Drives Strong Growth 
Jamie Dimon Warns Anthropic's Mythos AI Poses National Security Risks 
SEB Q2 Profit Rises on Strong Lending, Record Fee Income, Announces New Share Buyback 
Rio Tinto Reports Strong Q2 Iron Ore Sales, Maintains 2026 Production Outlook 
Paramount-Warner Bros. Discovery Merger Faces Lawsuit From 12 States 
NY Times Challenges Trump Administration Subpoenas Over Air Force One Report 
xAI Sues Man for Allegedly Using Grok to Generate AI Child Abuse Deepfakes 
DBS Targets S$1 Trillion Wealth AUM by 2030 Amid Asia Wealth Boom 
Eli Lilly Eyes AtaiBeckley Acquisition to Expand Psychedelic Mental Health Pipeline 
Apple Intelligence Cleared for China as Alibaba and Baidu AI Power iPhone Features 
SK Hynix Stock Soars as AI Memory Demand Outlook Fuels Chip Rally 
CAMBRIDGE, Mass., Feb. 01, 2016 -- Genocea Biosciences, Inc. (NASDAQ:GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced that Chip Clark, president and chief executive officer, will present a company overview at the upcoming 2016 BIO CEO & Investor Conference on Monday, February 8, 2016 at 5:00 p.m. ET in New York, NY.
A live webcast of the presentation can be accessed by visiting the “Events and Presentations” tab of the investor relations section of the Genocea website at http://ir.genocea.com. A replay of the webcast will be archived for 30 days following the presentation.
About Genocea Biosciences, Inc.
Genocea is harnessing the power of T cell immunity to develop life-changing vaccines and immunotherapies. T cells are increasingly recognized as a critical element of protective immune responses to a wide range of diseases, but traditional discovery methods have proven unable to identify the targets of such protective immune response. Using ATLAS, its proprietary technology platform, Genocea identifies these targets to potentially enable the rapid development of medicines to address critical patient needs. Genocea's pipeline of novel clinical stage T cell-enabled product candidates includes GEN-003 for genital herpes, GEN-004 for the prevention of infection by all serotypes of pneumococcus, and earlier-stage programs in chlamydia, genital herpes prophylaxis, malaria and cancer immunotherapy. For more information, please visit the company's website at www.genocea.com.
For media: Liz Bryan Spectrum Science Communications, Inc. O: 202-955-6222 [email protected] For investors: Jonathan Poole Genocea Biosciences, Inc. O: 617-876-8191 [email protected]
